These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22553309)

  • 1. Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control.
    Roomp K; Rand J
    J Feline Med Surg; 2012 Aug; 14(8):566-72. PubMed ID: 22553309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine.
    Roomp K; Rand J
    J Feline Med Surg; 2009 Aug; 11(8):668-82. PubMed ID: 19592286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin detemir treatment in diabetic cats in a practice setting.
    Hoelmkjaer KM; Spodsberg EM; Bjornvad CR
    J Feline Med Surg; 2015 Feb; 17(2):144-51. PubMed ID: 24938314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feline diabetes mellitus: clinical use of long-acting glargine and detemir.
    Bloom CA; Rand J
    J Feline Med Surg; 2014 Mar; 16(3):205-15. PubMed ID: 24563492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of diabetic remission, predictors of remission and survival in cats using a low-cost, moderate-intensity, home-monitoring protocol and twice-daily glargine.
    Gottlieb S; Rand JS; Anderson ST
    J Feline Med Surg; 2024 Apr; 26(4):1098612X241232546. PubMed ID: 38661475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISFM consensus guidelines on the practical management of diabetes mellitus in cats.
    Sparkes AH; Cannon M; Church D; Fleeman L; Harvey A; Hoenig M; Peterson ME; Reusch CE; Taylor S; Rosenberg D;
    J Feline Med Surg; 2015 Mar; 17(3):235-50. PubMed ID: 25701862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN; Dündar N; Eren E
    J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of diabetic cats with long-acting insulin.
    Roomp K; Rand JS
    Vet Clin North Am Small Anim Pract; 2013 Mar; 43(2):251-66. PubMed ID: 23522171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
    Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
    Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
    Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
    Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.